These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 32539916)

  • 41. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.
    Spence R; Mandagere A; Harrison B; Dufton C; Boinpally R
    J Pharm Sci; 2009 Dec; 98(12):4962-74. PubMed ID: 19455620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV; Aleevskaya AM
    Kardiologiia; 2020 Aug; 60(7):28-35. PubMed ID: 33155938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of pulmonary arterial hypertension in the Camerino area of central Italy and savings resulting from generic bosentan.
    Natali S; Palmieri M; Polidori C
    Eur J Hosp Pharm; 2020 Mar; 27(2):100-102. PubMed ID: 32133136
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
    Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
    Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
    Heresi GA; Love TE; Tonelli AR; Highland KB; Dweik RA
    Am J Respir Crit Care Med; 2018 Oct; 198(8):1090-1093. PubMed ID: 29949380
    [No Abstract]   [Full Text] [Related]  

  • 47. A highly sensitive LC-MS/MS method for concurrent determination of sildenafil and rosiglitazone in rat plasma.
    Rashid J; Ahsan F
    J Pharm Biomed Anal; 2016 Sep; 129():21-27. PubMed ID: 27392173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
    Liang F; Yang S; Yao L; Belardinelli L; Shryock J
    Hypertension; 2012 Mar; 59(3):705-11. PubMed ID: 22311911
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P; Pulido T
    Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
    Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
    Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
    Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
    BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simple and sensitive liquid chromatography-tandem mass spectrometry methods for quantification of tadalafil in rat plasma: application to pharmacokinetic study in rats.
    Lee JH; Oh JH; Lee YJ
    Arch Pharm Res; 2013 Apr; 36(4):457-63. PubMed ID: 23435913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.
    Li J; Yang ZY; Wang S; Yuan P; Zhao QH; Gong SG; Qiu HL; Luo CJ; Li HT; Zhang R; Wu WH; Liu JM; Wang L; Liu SS; Jiang R
    Front Cardiovasc Med; 2022; 9():977110. PubMed ID: 36568539
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 57. [Pulmonary arterial hypertension: changing approaches to management].
    Sidorenko BA; Preobrazhenskiĭ DV; Batyraliev TA; Belenkov IuN
    Kardiologiia; 2011; 51(1):100-8. PubMed ID: 21626809
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LC-ESI-MS/MS analysis of phosphodiesterase-5 inhibitors and their analogues in foods and dietary supplements in Korea.
    Jeong JH; Lee JH; Kim HJ; Park HJ; Hwang IS; Han KM; Yoon CY; Cho S; Kim WS
    Food Addit Contam Part B Surveill; 2016; 9(1):1-8. PubMed ID: 25263347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.